United States Patent 10,696,660 (GVHD oral treatment): claim scope, structural coverage, and US patent estate risk map
US Patent 10,696,660 claims an oral small-molecule method of treatment for graft-versus-host disease (GVHD) using a compound defined by broad substituent classes around a “formula XXXI” (and dependent coverage to “formula XXXIVa” and a third “formula” set). The operative claim is a method-of-use claim covering a large chemical space (multiple variable positions, multiple heterocycles, and extensive substituent permutations), where the patent risk is determined less by literal formula matching and more by whether a generic or follow-on entrant selects a covered substructure for the defined variables R13, R14, X, R16, R17, R2, R3, n, m and whether their product is orally administered to treat GVHD.
Note: A complete, business-grade “landscape” (other US-family patents, assignees, prosecution history, litigation status, and Orange Book tie-ins) cannot be produced from the claim text alone. The scope below is limited to what is inferable directly from the provided claims.
What does US 10,696,660 claim: oral method-of-treatment for GVHD using formula XXXI / XXXIVa?
Short answer: The independent claim covers a therapeutically effective oral administration of a compound of formula XXXI (or a pharmaceutically acceptable salt) to a human subject for treatment of GVHD. It also broadly enumerates allowable substitutions at key structural variables (R13, R14, X, R16, R17, R2, R3, n, m). Dependent claim 2 narrows the compound subset to formula XXXIVa. Claim 3 adds another covered formula subset.
Claim type and enforceability focus
- Method-of-use: enforcement is tied to the act of treating GVHD and the oral administration of the covered compound (and its salts).
- This type often creates product-specific and indication-specific infringement pathways:
- If a competitor sells a covered compound and labels/uses it for GVHD, infringement risk is higher.
- If the competitor treats GVHD using an uncovered chemical variant or a different route, risk drops.
What triggers infringement on the face of the claims
The following elements are required simultaneously:
- Human subject with GVHD (treatment intent or practice).
- Oral administration.
- Therapeutically effective amount.
- The administered entity must be:
- a compound of formula XXXI, or
- a pharmaceutically acceptable salt thereof.
Dependent claim 2 requires the compound to fall under formula XXXIVa; claim 3 requires a further formula subset.
Which chemical features define the covered compound space (R13/R14, X, R16/R17, n/m), and how broad is it?
Short answer: The claim uses broad combinatorial definitions for substituents at multiple positions, including:
- aryl/heteroaryl and fused heterocycles,
- cycloalkyl and heterocyclic rings,
- multiple halogen and perfluoroalkyl options,
- flexible ring-closure options where R13 and R14 can join to form a ring (same for R16 and R17).
This makes the claim potentially broad at the structure level, even if the core scaffold underlying “formula XXXI” is specific.
Variable mapping and coverage breadth
1) R13 and R14: independent substituent options plus ring-closure option
-
R13 and R14 each independently can be:
- H
- C1–C8 alkyl
- C2–C8 alkenyl
- C2–C8 alkynyl
- —(C1–C6 alkyl)-O—(C1–C6 alkyl) (dialkyl ether)
- —(C1–C6 alkyl)-NR16R17 (dialkylamino linkage)
- —(C1–C6 alkyl)-C(=O)NR16R17 (amide linkage)
- aryl, aralkyl, heteroaryl
- C3–C7 cycloalkyl
- a 3–12 member heterocycle with up to 3 heteroatoms (optionally substituted)
-
Ring fusion option: R13 and R14 can be taken together to form a 3–12 membered heterocycle (up to 3 heteroatoms), optionally substituted.
Business implication: Competitors cannot “design around” by making R13/R14 “simple” substituents only; the claim covers both simple and heterocycle-forming substitutions and includes multiple linkages that incorporate R16/R17.
2) R16 and R17: extensive substituent menu (and ring-closure)
-
R16 and R17 each independently are selected from:
- H
- C1–C8 alkyl, C2–C8 alkenyl, C2–C8 alkynyl
- —(C1–C6 alkyl)-O—(C1–C6 alkyl) (dialkyl ether)
- aryl, aralkyl, heteroaryl
- C3–C7 cycloalkyl
- a 3–12 membered heterocycle with up to 3 heteroatoms (optionally substituted)
-
Ring closure option: R16 and R17 can join to form a 3–12 membered heterocycle (up to 3 heteroatoms), optionally substituted.
Business implication: The dependent linkage options using NR16R17 and C(=O)NR16R17 means that many “amine-bearing” variants and amide variants may still fall within scope if they align to the scaffold positions defined in formula XXXI.
3) X: minimal discriminator (bond, O, NH, or alkyl)
X is selected from:
- a covalent bond,
- O,
- NH,
- C1–C6 alkyl.
Business implication: This is not a narrow definition. Any competitor hoping to avoid by swapping in O/NH variants faces broad claim coverage.
4) R2 and R3: lower alkyl and common hetero-substituted options
Each of R2 and R3 can be independently selected from:
- lower alkyl,
- CN,
- halo,
- hydroxy,
- lower alkoxy,
- amino,
- perfluoro lower alkyl.
Business implication: These are common medicinal chemistry substituents; the claim does not carve out common design-around positions.
5) n and m: modest integer ranges
Business implication: The claim likely covers multiple substitution patterns on the core scaffold (for example, multiple ring or linker units) without being unlimited.
How does dependent claim 2 (formula XXXIVa) narrow scope, and what is the practical difference vs claim 1?
Short answer: Claim 2 limits the compound from the broad “formula XXXI” space to a narrower set of compounds explicitly defined by formula XXXIVa (while keeping the same method elements: oral administration for GVHD).
What claim 2 changes
- Claim 2 uses the same high-level method structure:
- GVHD treatment
- human subject
- oral administration
- therapeutically effective amount
- salts allowed
- But swaps the compound definition:
- claim 1: compound is of formula XXXI
- claim 2: compound is of formula XXXIVa
Business implication: If a competitor’s compound falls outside formula XXXI literal coverage but inside XXXIVa, claim 2 remains relevant. Conversely, if XXXIVa is a subset of XXXI, claim 1 may already cover the same compound. Without the structural depiction, the exact overlap cannot be confirmed.
What does claim 3 add: “formula” subset coverage beyond XXXI/XXXIVa?
Short answer: Claim 3 adds a further compound formula subset as an independent alternative to claims 1 and 2, still within the oral GVHD treatment method.
Business implication: Multiple “formula alternatives” are typical in continuation sets where the patent owner wants to cover:
- closely related scaffold variants, and
- different core substituent arrangements
under the same method-of-use concept.
How would a generic or follow-on designer assess “design-around” risk under these claims?
Short answer: Risk is driven by whether the competitor’s oral GVHD compound matches the claim’s variable definitions and scaffold constraints of formula XXXI/XXXIVa (and whether their product is used for GVHD).
Practical “risk points” to evaluate in silico and in regulatory dossiers
- Route of administration
- The claim is limited to oral administration. Intravenous or topical routes can avoid the method claim element.
- Indication linkage
- Even for a covered compound, enforcement typically depends on treating GVHD.
- Core scaffold alignment
- The claim text provides variable ranges but not the core ring/attachment pattern. A competitor must test literal coverage (and likely equivalents, depending on claim construction).
- Substituent classes
- The claim permits many common substituent categories, including ring-forming options at R13/R14 and R16/R17 and broad X options (bond/O/NH/alkyl).
- Amine/amide linkages
- The presence of —(C1–C6 alkyl)-NR16R17 and —(C1–C6 alkyl)-C(=O)NR16R17 expands coverage to many nitrogen-containing variants.
What is the US patent landscape for 10,696,660 (family size, other claims, expiration), and what does it mean for freedom to operate?
Short answer: A complete landscape cannot be generated from the claim text provided because it requires at minimum:
- the issued patent bibliographic data (filing date, earliest priority, assignee),
- the patent family members,
- USPTO publication numbers / continuation relationships,
- prosecution and claim amendments,
- and any Orange Book / NDA/BLA linkage.
No such data is included in the prompt, so no reliable expiration timeline, family breadth, or litigation status can be stated.
Key Takeaways
- US 10,696,660 is a broad method-of-use patent for oral treatment of GVHD using compounds defined by formula XXXI, with dependent coverage to formula XXXIVa and an additional formula subset in claim 3.
- The compound definitions are structurally expansive: R13/R14 and R16/R17 support both independent substituents and ring-closure options; X is broadly defined; R2/R3 include common medicinal substituents (halo, CN, hydroxy, alkoxy, amino, perfluoroalkyl).
- Design-around through “ordinary” substituent swaps is unlikely to be sufficient. The main viable levers are:
- avoid oral administration (if commercially feasible),
- avoid GVHD indication use, and
- ensure the competitor’s compound does not fall within the literal scaffold constraints of formula XXXI/XXXIVa.
- A full patent estate, expiration, and litigation-risk analysis requires bibliographic and family data not provided here.
FAQs
-
Is US 10,696,660 limited to orally administered GVHD therapies?
Yes. The method claim requires oral administration of a therapeutically effective amount to treat GVHD.
-
Does the claim cover pharmaceutically acceptable salts?
Yes. Each covered compound is defined “or a pharmaceutically acceptable salt thereof.”
-
Can R13 and R14 form a ring in the claimed compounds?
Yes. R13 and R14 can be taken together to form a 3–12 member heterocycle (up to 3 heteroatoms), with optional substitutions.
-
Does the claim allow nitrogen-containing linkages such as amines and amides?
Yes. The definitions include —NR16R17 and —C(=O)NR16R17 linkages, with broad definitions for R16/R17.
-
What is the likely fastest design-around pathway: chemistry or dosing/indication?
Route and indication are direct claim elements; chemistry must avoid the scaffold coverage of formula XXXI/XXXIVa and related dependent formula sets.
